Helicobacter pylori is an important risk factor of duodenal ulcer (DU). Although many virulence factors of H. pylori have been identified, few have been reported to show an association with the pathogenesis of DU. The aims of this study were to identify H. pylori antigens showing a high seropositivity in DU and to develop a platform for rapid and easy diagnosis for DU. Because DU and gastric cancer (GC) are considered clinical divergent gastroduodenal diseases, we compared two-dimensional immunoblots of an acid-glycine extract of an H. pylori strain from a patient with DU probed with serum samples from 10 patients with DU and 10 with GC to identify DU-related antigens. Of the 11 proteins that were strongly recognized by serum IgG from DU patients, translation elongation factor EF-G (FusA), catalase (KatA), and urease ␣ subunit (UreA) were identified as DU-related antigens, showing a higher seropositivity in DU samples (n ‫؍‬ 124) than in GC samples (n ‫؍‬ 95) (FusA, 70.2 versus 45.3%; KatA, 50.8 versus 41.1%; UreA, 44.4 versus 27.4%). In addition, we found that the use of multiple antigens improved the discrimination between patients with DU and those with GC as the odds ratios increased from 1.82 (95% confidence interval (CI), 0.79 -4.21; p ‫؍‬ 0.1607) for seropositivity for FusA, KatA, or UreA alone to 4.95 (95% CI, 2.05-12.0; p ‫؍‬ 0.0004) for two of the three antigens and to 5.71 (95% CI, 1.86 -17.6; p ‫؍‬ 0.0024) for all three antigens. Moreover a protein array containing the three DU-related antigens was developed to test the idea of using multiple biomarkers in diagnosis. We conclude that FusA, KatA, and UreA are DU-related antigens of H. pylori, and the combination of these on a protein array provided a rapid and convenient method for detecting serum antibody patterns of DU patients.
Helicobacter pylori is the major factor involved in the pathogenesis of gastritis, gastric ulcer, duodenal ulcer (DU), 1 and gastric cancer (GC). It is known that this bacterium infects more than half the world's population (1) . However, the clinical outcomes of H. pylori infection are highly variable and influenced by both bacterial factors and host immune responses. Most infected persons are asymptomatic with no apparent disease, but 6 -20% have duodenal ulceration, and a small proportion develop GC (2) . DU and GC are considered clinically divergent gastroduodenal diseases in which the pattern of gastritis is regarded as the major factor in the pathogenesis. Antral-predominant gastritis leads to increased acid production and duodenal ulceration, whereas corpus-predominant atrophic gastritis leads to acid reduction and a higher risk of developing GC (3, 4) .
It has been recognized that the inflammation induced by H. pylori infection is a factor related to the pathogenesis of gastroduodenal diseases. Chronic active gastritis, the hallmark of H. pylori infection, is characterized by infiltration of the mucosa by neutrophils, lymphocytes, and monocytes/macrophages (5) . A strong humoral immune response to a variety of H. pylori antigens is also elicited (6) . H. pylori antigens are therefore regarded as potential candidates for biomarkers or vaccines (7) . Serological tests are noninvasive methods for diagnosing H. pylori infection. Moreover evaluation of the humoral immune responses to H. pylori antigens by immunoblotting appears to be more sensitive than ELISA for detecting low abundance antibodies. Importantly ϳ70% of patients with DU are infected with H. pylori (8, 9) . The aims of the present prospective study were to identify DU-related antigens by two-dimensional (2D) immunoblotting and mass spectrometry and to develop a platform for detecting antibody patterns for diagnostic use.
Protein array technology has been shown to be a useful tool for multiplexed measurements and proteomics studies. Protein arrays can be classified into two types, analytical and functional protein arrays. The most representative analytical protein arrays are antibody arrays. Functional protein arrays have been applied to many fields, including studies of proteinprotein, protein-DNA, and protein-drug interactions; biomarker discovery; and clinical diagnosis (10) . The binding of humoral antibodies to allergens, autoantigens, cancer-specific antigens, or infectious organisms is the basis of the design of protein arrays for biomarker discovery and clinical diagnosis (11) (12) (13) (14) . Applying this concept, we wished to develop a DUrelated protein array, which can be used for immunodiagnostics in the form of miniaturized and multiplexed assays.
In this study, we used a proteomics approach to identify DU-related antigens of H. pylori by comparing the profiles of 2D immunoblots of an acid-glycine extract of H. pylori probed with DU and GC sera. We identified three DU-related antigens, FusA, KatA, and UreA, all of which were more frequently recognized by DU sera than GC sera. Statistical analysis of the data showed that the discrimination power of the threeantigen combination was greater than that of a single antigen. We therefore developed a DU-related protein array that can be used to simultaneously and rapidly detect the reactions of serum antibodies to different DU-related antigens.
EXPERIMENTAL PROCEDURES
Isolation of the H. pylori Strain and Culture Conditions-H. pylori strain HD12 was isolated from endoscopic biopsy samples from the stomach of a patient with DU at the National Taiwan University Hospital. The bacteria were cultured on a BBL TM Stacker TM plate (BD Biosciences) at 37°C under microaerobic conditions.
Patients and Serum Samples-Serum samples were prospectively collected from individuals who participated in a national project for the investigation of H. pylori and gastroduodenal disorders in Taiwan between December 1999 and December 2001. Our study protocol was approved by both the Institutional Research Board and the Department of Health, Executive Yuan, Taiwan. One hundred and twenty-four patients with DU who received an upper gastrointestinal endoscopic examination were enrolled. Ninety-five patients with GC who underwent curative gastrectomy at our institution were also enrolled. H. pylori status was determined by culture and/or histological examination of gastric biopsy specimens. In addition, 40 subjects with a normal appearance of the gastric mucosa and no evidence of H. pylori infection were selected as controls. Fasting serum samples were collected from all participants, catalogued, aliquoted, and stored at Ϫ80°C. Aliquots were only thawed once prior to analysis.
Two-dimensional Electrophoresis and Immunoblotting-Cell surface proteins were extracted from H. pylori using an acid-glycine extraction procedure as described previously (15) . Proteins in the H. pylori acid-glycine extract were precipitated using trichloroacetic acid (20%) and separated by 2D electrophoresis as described previously (16) . Briefly the protein extract was incubated with 2D sample buffer (8 M urea, 2% Pharmalyte, pH 3-10, 60 mM DTT, 4% CHAPS, bromphenol blue), the first dimension of the 2D gel was run on IPG strips (Immobiline DryStrip, pH 3-10, 11 cm, GE Healthcare), and the second dimension was run on 12.5% SDS-polyacrylamide gels. For immunodetection, the proteins on the gel were transferred to a PVDF membrane (Millipore, Bedford, MA). Then the membrane was blocked by incubation for 1 h at room temperature in blocking buffer (26 mM Tris-HCl, 150 mM NaCl, pH 7.5, 1% skimmed milk) and incubated overnight at 4°C with serum samples from DU patients or GC patients or pooled normal sera (1:1000 in blocking buffer containing 0.05% Tween 20) and then for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-human IgG (Chemicon, Temecula, CA). Then bound antibody was detected using 3-amino-9-ethylcarbazole (Sigma) as substrate.
Protein Identification-The individual Coomassie Blue-stained protein spots were excised and subjected separately to in-gel tryptic digestion. Briefly the spots were destained using 50 mM NH 4 Table I and Supplemental Table 1 .
Cloning and Purification of the Recombinant Proteins-H. pylori was lysed, the lysate was subjected to RNase treatment, and then genomic DNA was extracted using phenol-chloroform and precipitated with 70% ethanol. To amplify the DNA fragments containing the H. pylori fusA gene, katA gene, ureA gene, and flaA gene (control) by PCR, the primer pairs used were: fusA: sense, 5Ј-GGT ACC ATG GCT AGA AAA ACC CCA-3Ј; antisense, 5Ј-CTG CAG TCA GCC TTT GCG TTT TTC-3Ј; katA: sense, 5Ј-GAA TTC GAT GGT TAA TAA AGA TGT GAA-3Ј; antisense, 5Ј-CTC GAG CTT TTT CTT TTT TGT GTG GT-3Ј; ureA: sense, 5Ј-GGA TCC ATG AAA CTC ACC CCA-3Ј; antisense, 5Ј-GGA TCC TTA CTC CTT AAT TGT T-3Ј; and flaA: sense, 5Ј-GGA TCC ATG GCT TTT CAG GTC AAT-3Ј; antisense, 5Ј-GGT ACC CTA AGT TAA AAG CCT TAA G-3Ј. PCR was performed using 30 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min followed by a final extension at 72°C for 15 min. The fusA, ureA, and flaA gene fragments were cloned into the expression vector pQE30 (Qiagen, Hilden, Germany) and transformed into Escherichia coli strain M15, whereas the katA gene fragment was cloned into the pET-22b(ϩ) vector (Novagen, Madison, WI) and transformed into E. coli strain BL21. For expression of recombinant proteins, cells were grown to an A 600 value of 0.6, induced with 1 mM isopropyl ␤-D-thiogalactoside, and harvested after 6 h at 25°C (for UreA), 2 h at 37°C (for FlaA), or 4 h at 37°C (for FusA and KatA). The recombinant proteins were dissolved in binding buffer (20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, pH 7.9) containing 8 M urea and purified on a Ni 2ϩ -chelating Sepharose column (GE Healthcare).
Serologic Study-An H. pylori acid-glycine extract and recombinant FusA, KatA, UreA, and FlaA were electrophoresed on 12.5% SDS-polyacrylamide gels, transferred to the PVDF membrane, and then subjected to immunoblotting using serum samples from patients with DU or GC or from normal controls diluted 1:1000 as described above.
Statistical Analysis-Statistical analysis was performed using SAS version 9.1 (SAS Institute Inc., Cary, NC). The odds ratio (OR) and 95% confidence interval (CI) were estimated by multiple logistic regression analysis. Comparisons between tests of serum reactions on protein arrays were made using Student's t test. A p value of Ͻ0.05 was considered statistically significant.
Protein Array Fabrication-Poly(L-lysine)-coated slides were placed in an OmniGrid arrayer (GeneMachines, San Carlos, CA) and four SMP3 printing pins (TeleChem, Sunnyvale, CA) with a tip diameter of 100 m were used to generate the protein arrays. All proteins were spotted in quadruplicate at three different concentrations (100, 300, and 600 g/ml) diluted with 0.14 -2 M urea in PBS. Each protein array contained the control spots, human IgG in three dilutions (one normal serum was diluted with PBS to 1:1500, 1:1000, and 1:500). The resulting protein chips were stored in a desiccator.
Serum Reaction on Protein Arrays-All reactions were performed at room temperature. The chips were blocked for 2 h with 2% BSA in TBST (20 mM Tris, 137 mM NaCl, 0.1% Tween 20, pH 7.6) in a humidified atmosphere and then incubated with the test sera (1:100 in 2% BSA in TBST) for 1 h. Following three TBST washes, the chips were incubated for 1 h in the dark with Cy3-conjugated anti-human IgG antibody (1:500 in 2% BSA in TBST; Abcam, Cambridge, UK) and then washed three times in TBST and twice in distilled water. All incubation steps were performed in a volume of 50 l underneath a cover slide. Following air drying, the protein chips were imaged using a GenePix TM 4000B scanner (Axon Instruments, Union City, CA), and image analysis was performed using GenePix Pro 6.0 (Axon Instruments).
RESULTS

Identification of DU-related Antigens of H. pylori by 2D
Immunoblot Analysis-To identify the DU-related antigens of H. pylori, we first examined the one-dimensional immunoblot profiles of the acid-glycine-extracted bacterial proteins probed with sera from H. pylori-infected patients with DU. The molecular masses of the immunoreactive proteins ranged from 23 to 97 kDa (Fig. 1A) . The binding pattern of each serum sample was distinct and unique. Moreover several proteins were recognized by sera from normal individuals (Fig. 1B) . We then performed 2D electrophoresis on the bacterial proteins and examined the patterns of the 2D immunoblots probed with sera from 10 patients with DU in the active stage. Fig. 2A shows the complex 2D profile of the H. pylori acid-glycineextracted proteins after silver staining. The representative 2D immunoblot probed with one DU serum is shown in Fig. 2B . Numerous protein spots recognized by the DU sera were observed. The majority of the recognized antigens had molecular masses greater than 30 kDa under reducing conditions, and those showing the strongest reaction had molecular masses greater than 50 kDa. To determine which antigens were DU-related and non-DU-related, we compared the frequency of recognition of these by sera from patients with DU and GC (n ϭ 10) and identified the proteins by nano-LC-MS/MS analysis (Table I and Supplemental Table 1 ). The representative 2D immunoblot probed with one GC serum is shown in Fig. 2C . Several proteins recognized at a high frequency by both DU and GC sera were flagellar hook protein, flagellar hook-associated protein (FliD), molecular chaperone DnaK, urease ␤ subunit, flagellin A, flagellin B, and serine protease (HtrA). Importantly comparison of DU and GC prevalence data showed that translation elongation factor EF-G (FusA; DU versus GC, 70 versus 40%), catalase (KatA; 100 versus 50%) and urease ␣ subunit (UreA; 40 and 80% versus 20%) were potential candidates for DU-related antigens. Fig.  3 shows the reactivity of FusA, KatA, and UreA in 2D immunoblots probed with 10 DU sera. The location of FusA was close to a spot with strong immunoreactivity. The different isoforms of KatA were recognized equally well by DU sera; in contrast, 40% of DU sera recognized two of three UreA isoforms, and 40% of DU sera recognized all UreA isoforms.
Clinical Significance of FusA, KatA, and UreA Seropositivity-To further examine the clinical significance of FusA, KatA, and UreA as potential candidates for DU-related antigens, we expressed the recombinant His-tagged fusion proteins in E. coli. Recombinant FusA, KatA, and UreA with apparent molecular masses of 80, 63, and 28 kDa, respectively, were successfully expressed and purified (Fig. 4, lanes 1-3) . The identity of the purified proteins was confirmed by nano-LC-MS/MS, and their antigenicity was examined by immunoblot analysis using pooled sera from DU patients (Fig. 4, lanes  4 -6) . They were then used in an immunoblot assay using a series of clinical samples including sera from H. pylori-infected patients with DU (n ϭ 124) or GC (n ϭ 95) or non-H. pylori-infected normal individuals (control, n ϭ 40). As shown in Table II Combination of Multiple Antigens as Biomarkers of DU Disease-To evaluate whether a combination of multiple antigens increased the ability to distinguish patients with DU from those with GC and normal individuals, we compared the frequency of seroreactivity with a single antigen (FusA, KatA, or UreA) and with combinations of these antigens in gastroduodenal diseases (Table III) . Comparing the results for the DU samples with those for the GC samples, the odds ratios increased with the number of recognized antigens, going from 1.82 (95% CI, 0.79 -4.21; p ϭ 0.1607) for a single recognized antigen to 4.95 (95% CI, 2.05-12.0; p ϭ 0.0004) for two recognized antigens and to 5.71 (95% CI, 1.86 -17.6; p ϭ 0.0024) for three recognized antigens. Similarly when the results for the DU samples were compared with those for the GC samples and normal samples combined, the odds ratios again increased with the number of recognized antigens: 3.14 (95% CI, 1.46 -6.77; p ϭ 0.0035) for a single antigen, 9.87 (95% CI, 4.35-22.4; p Ͻ 0.0001) for two antigens, and 12.5 (95% CI, 4.23-36.8; p Ͻ 0.0001) for three antigens. Using combinations of two of the three antigens, each pair had a significantly higher odds ratio than the single antigen when DU samples were compared with GC samples alone or the population of GC and normal individuals combined. Importantly the combination of KatA and UreA led to the best 
Development of a DU-related Antigen Protein
Array-To improve the efficiency and convenience of diagnostic usage, we designed a multiple protein array including DU-related antigens and a non-disease-related antigen in a poly(L-lysine)-coated slide. The DU-related antigens were FusA, KatA, and UreA, whereas FlaA was selected as a positive control antigen to monitor the experimental performance. We found that FlaA was recognized by sera from H. pylori-infected persons and non-infected persons. All antigens were spotted at three different concentrations (100, 300, and 600 g/ml) to show the trend of antigen-antibody recognition. Human IgG was also included at three serial dilutions for interchip comparison. The chips were incubated with sera from six DU patients and seven normal individuals. Based on the immunoblot analysis, six DU patients whose serum IgG recognized all the DUrelated antigens were selected. In contrast, none of the DUrelated antigens were recognized by serum IgG from the seven normal individuals. The results of chip reactions with six DU sera and four normal sera are shown in Fig. 5A . The analysis of human IgG showed a low coefficient of variation (26.4, 28.9 , and 3.6% for 1:1500, 1:1000, and 1:500, respectively), indicating good reproducibility between chip-serum incubations. When comparing DU sera with normal sera using the average intensity of fluorescence, obviously distinct two groups were observed at each concentration of each protein (Fig. 5B) . This experiment demonstrated that the diagnosis testing of a combination of antigens could be performed using a protein array.
DISCUSSION
H. pylori is an important factor in the pathogenesis of DU (17) . Clinically about 70% of endoscopically diagnosed DU patients are infected with H. pylori (8, 9 ). To identify potential candidate H. pylori antigens related to DU, we used a proteomics approach to analyze H. pylori antigens from a strain clinically isolated from a patient with DU in the active stage and found 11 proteins, which reacted strongly with sera from DU patients. Most of these were recognized by all of the DU (lanes 1 and 4), KatA (lanes 2 and 5) , and UreA (lanes 3 and 6) were electrophoresed on a 10% SDS gel and detected by Coomassie Blue (lanes 1-3) or transferred to a PVDF membrane and immunoblotted with pooled DU sera (lanes 4 -6) . Lane M, molecular mass markers. sera used in the 2D immunoblot analysis in our study and most have been reported as immunoreactive proteins in previous studies (18 -20) . Kimmel et al. (18) identified 29 antigens that reacted with sera from patients with different gastroduodenal diseases but failed to show a correlation between antibody patterns in patients and particular diseases. Haas et al. (19) probed H. pylori proteins from the strain 26695 with sera from patients with active H. pylori infection suffering from gastritis, ulcer, or gastric cancer. They identified 32 H. pylori antigens reactive with H. pylori-positive sera and characterized several antigens differentially recognized by sera from gastritis and ulcer patients. Mini et al. (20) analyzed the H. pylori proteins of three strains isolated from patients with chronic gastritis, duodenal ulcer, and GC and probed with sera from patients with GC and DU. They identified 30 antigens and divided these into three groups: pathogen-unspecific, ulcer-associated, and gastric cancer-associated groups. Many immunoreactive proteins of H. pylori have been reported by 2D immunoblot studies, such as those mentioned above, but, as far as we are aware, only GroES has been confirmed to be associated with a particular disease (21) . In this study, translation elongation factor EF-G (FusA) and flagellar hook protein were identified as H. pylori antigens for the first time. Furthermore we also identified three of the 11 proteins as candidate DU-related antigens by comparing the antigenic profile of H. pylori proteins from a DU strain probed with sera from patients with DU and GC. In addition to the preliminary data derived from 2D immunoblots, recombinant FusA, catalase (KatA), and urease ␣ subunit (UreA) were used to screen a larger sample size of clinical sera from patients with DU and GC, and the results confirmed the association with DU.
The physiological function of FusA is important for the translocation of peptidyl-tRNA from the A site to the P site within the ribosome (22) . In addition, it is also an essential protein in the dissociation of the post-termination complex (23) . In Staphylococcus aureus and most Gram-negative bacteria, such as Salmonella typhimurium, mutation of FusA causes fusidic acid resistance (24, 25) . H. pylori UreA, the ␣ subunit of urease, is mainly found in the cytoplasm but is also presents at the cell surface and is secreted out of the bacterium (26, 27) . H. pylori urease, an important H. pylori virulence factor, hydrolyzes urea into NH 3 and CO 2 and allows this bacterium to survive in the acidic gastric environment (28) . Haas et al. (19) reported that UreA showed a significant difference in reactivity with sera from patients with gastroduodenal ulcer compared with gastritis. From our 2D immunoblot data, the frequency of reactivity with FusA and UreA in DU patients was 70 and 40 and 80% (n ϭ 10), respectively. It was similar when a larger sample size was screened using the recombinant FusA (70.2%, n ϭ 124), whereas it was lower using the recombinant UreA (44.4%, n ϭ 124).
H. pylori KatA was purified and characterized by Hazell et al. (29) and was found to be located in both the cytoplasm and periplasm (30) . In addition, it is reported to be secreted out of H. pylori (31) , and its catalase activity is essential for the survival of the bacterium at the phagocyte surface (32) . Atanassov et al. (33) showed that the frequency of KatA seropositivity in patients with gastroduodenal ulcer was greater than 90% (n ϭ 55), whereas that in patients with non-ulcer dyspepsia was 67% (n ϭ 30) using an extract of a gastritis strain of H. pylori and 93% using the ATCC 43579 strain. In our study, as with the UreA data, the frequency of KatA seroreactivity in DU patients was 100% (n ϭ 10) by 2D immunoblot analysis but was 50.8% (n ϭ 124) by larger sample size screening using recombinant KatA. Although KatA seropositivity was not associated more with DU than with GC, it improved the prediction of DU when combined with FusA and/or UreA (Table III) . KatA is therefore also an important DU-related antigen. Our statistical analysis revealed that combinations of antigens improved the ability to distinguish between patients with DU and GC and normal individuals. The three-antigen combination gave excellent discrimination, and this phenomenon also implies the value of each antigen related to DU disease. However, heterogeneity of the host immune response to different H. pylori antigens may explain the relatively low occurrence of multiseropositivity in particular individuals in this study. For the preliminary examination of the risk of DU in the clinic, we suggest a rule considering positivity of two or three antigens as high risk to DU to compensate for this phenomenon.
H. pylori infection can be diagnosed by noninvasive methods or by endoscopy. Serologic testing, a noninvasive method, is inexpensive and widely used for the diagnosis of H. pylori infection before treatment (34) . Generally patients only agree to invasive endoscopy when they have alarming symptoms, such as stomachache, anemia, or gastrointestinal bleeding. Despite advances in therapies, gastrointestinal bleeding is still a cause of morbidity and mortality (35) . Serologic tests are more acceptable and can be carried out in a routine physical examination. Following a finding of seropositivity for two or three antigens (i.e. FusA, KatA, and UreA), patients would be recommended to undergo endoscopic ex- FIG. 5 . Development of a DU-related protein array for diagnosis. A, all proteins were spotted in quadruplicate at three different concentrations (100, 300, and 600 g/ml) diluted with 0.14 -2 M urea in PBS. Each protein array contained human IgG at three dilutions (one normal serum was diluted with PBS to 1:1500, 1:1000, and 1:500) for interchip comparison. FlaA was used as a positive control antigen to monitor the experimental performance. The chips were incubated with sera from DU patients and normal individuals, and bound antibody was detected by the fluorescence of the Cy3-conjugated anti-human IgG (hIgG) antibodies. B, comparison of the serum reactions of six DU patients and seven normal individuals with the three DU-related antigens, FusA, KatA, and UreA. Student's t test was used for statistical evaluation (*, p Ͻ 0.05). N, normal.
amination. We believe this concept will promote the early detection and treatment of DU disease.
To apply the idea of diagnosis using multiple biomarkers, we constructed a protein array containing the three DU-related antigens and compared the antibody binding patterns of sera from DU patients and normal individuals. At each concentration of each of the three antigens, the signal intensity was higher with DU sera than with normal sera. Although the serum reaction using an antigen concentration of 100 g/ml was able to distinguish the DU group from the controls, the use of a single cutoff value for a single protein concentration might lead to false positive or false negative results. We therefore used three concentrations of each antigen to monitor the trend of signal intensities. As long as two of the three signal intensities were higher than each cutoff value of protein concentrations, the sample was considered seropositive for a particular antigen. This results in fewer false positives.
In conclusion, here we report a comparison of the reactivity of serum antibodies from DU and GC patients to the H. pylori proteome, leading to the identification of FusA, KatA, and UreA as DU-related antigens of H. pylori. We further demonstrate that the combination of these three antigens can be used as a biomarker as a preliminarily means of distinguishing patients with DU from those with GC. Moreover we have developed a DU-related protein array using the combination of these three antigens for the purpose of clinical diagnosis.
